Rebrand Opportunity Avomeen has rebranded under the Element name following its acquisition by Element Materials Technology. This presents a chance to align marketing and sales outreach with Element’s broader Life Sciences capabilities, potentially cross-selling regulatory submissions, testing services, and turnkey product development to expanded North American and global clients.

Life Sciences Expansion Element positions itself strongly in regulatory submissions and turnkey product development for life sciences. This creates opportunities to target pharmaceutical, biotech, and medical device companies seeking outsourced testing, analytical development, and on-site partnerships to accelerate regulatory approvals.

Regulatory Readiness With accredited capabilities and a focus on regulatory compliance (ISO 17025), there is a sales opening to engage clients needing validated testing workflows, quality systems support, and regulatory consulting to streamline submissions and reduce time-to-market.

On-site and Capacity Element emphasizes dedicated capacity, staffing, and on-site partnerships. This can be pitched to firms facing bottlenecks in internal labs, unpredictable testing demand, or needing scalable resources for clinical trials and formulation work.

Strategic Hiring Signals Notable leadership hires in formulation, clinical trial manufacturing, and lab operations indicate continued investment in core competencies. This suggests opportunities to approach life sciences segments prioritizing end-to-end development, manufacturing readiness, and quality assurance services.